Zydus Cadila gets nod for Clinical Trials of Antibodies cocktail

These antibodies are made by cloning unique white blood cells.

85
USFDA Approval
USFDA Approval

Last Updated on October 17, 2024 by The Health Master

New Delhi: The only Indian company Zydus Cadila which claims to have developed neutralising monoclonal antibodies (mAbs)-based cocktail for the treatment of C-19 has been given permission to conduct clinical trials by the Subject Expert Committee (SEC) of Central Drugs Standard Control Organisation (CDSCO), according to sources.

“SEC gives a recommendation for the Phase I and II clinical trials of Zydus Cadila’s biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) that can emerge as one of the main treatments for mild C-19,” the sources said.

These antibodies are made by cloning unique white blood cells. Domestic pharmaceutical major Zydus Cadila sought the Drug Controller General of India (DCGI) permission recently to undertake clinical trials.

Lab Testing Laboratory
Picture: Pixabay

Zydus said that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild C-19.

Currently, some of the hospitals are administering the cocktail of two fast-acting anti-bodies – Casirivimab and Imdevimab, the batch of the Roche Antibody Cocktail drug arrived in the country on May 24. The cost of a single antibody cockatail is Rs 59,750.

Another antibody cocktail that has received permission is Eli Lilly and Company, India announced that it has received permission for restricted emergency use of its antibody drugs, bamlanivimab 700 mg and etesevimab 1400 mg, in India for the treatment of patients with mild to moderate C-19 virus disease.

ICMR approved Self-test kit for C-19 launched

Serum Institute seeks DCGI’s nod to manufacture Sputnik V vaccine

Black fungus drug: Black marketing Racket busted

Zydus Cadila gets tentative USFDA nod for Osimertinib Tablets

Sun Pharma, Ferring Pharma sign agreement to launch CARITEC in India

USFDA accepts application from Lupin for Pegfilgrastim Biosimilar

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news